Cargando…

French Pharmacovigilance Public System and COVID-19 Pandemic

The current COVID-19 pandemic is an exceptional health situation including for drug use. As there was no known effective drug for COVID-19 at the beginning of the pandemic, different candidates were proposed. In this short article, we present the French public pharmacovigilance activities during thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Grandvuillemin, Aurélie, Drici, Milou-Daniel, Jonville-Bera, Annie Pierre, Micallef, Joelle, Montastruc, Jean Louis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769328/
https://www.ncbi.nlm.nih.gov/pubmed/33372244
http://dx.doi.org/10.1007/s40264-020-01034-y
_version_ 1783629300049641472
author Grandvuillemin, Aurélie
Drici, Milou-Daniel
Jonville-Bera, Annie Pierre
Micallef, Joelle
Montastruc, Jean Louis
author_facet Grandvuillemin, Aurélie
Drici, Milou-Daniel
Jonville-Bera, Annie Pierre
Micallef, Joelle
Montastruc, Jean Louis
author_sort Grandvuillemin, Aurélie
collection PubMed
description The current COVID-19 pandemic is an exceptional health situation including for drug use. As there was no known effective drug for COVID-19 at the beginning of the pandemic, different candidates were proposed. In this short article, we present the French public pharmacovigilance activities during this health crisis. Although COVID-19 is a confounding factor per se, owing to its potential for multi-organ damage including the heart and kidney, the quality of the transmitted data in adverse drug reaction reports, the timeliness of feedback from clinicians, and the real-time pharmacological and medical analysis by the French network of the regional pharmacovigilance centers made it possible to swiftly identify relevant safety signals. The French National Agency of Medicine was thus able to validate the data and convey their findings very early. This decentralized organization based on medical and pharmacological evaluation of case reports has proven to be efficient and responsive in this unique and challenging healthcare emergency.
format Online
Article
Text
id pubmed-7769328
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-77693282020-12-28 French Pharmacovigilance Public System and COVID-19 Pandemic Grandvuillemin, Aurélie Drici, Milou-Daniel Jonville-Bera, Annie Pierre Micallef, Joelle Montastruc, Jean Louis Drug Saf Current Opinion The current COVID-19 pandemic is an exceptional health situation including for drug use. As there was no known effective drug for COVID-19 at the beginning of the pandemic, different candidates were proposed. In this short article, we present the French public pharmacovigilance activities during this health crisis. Although COVID-19 is a confounding factor per se, owing to its potential for multi-organ damage including the heart and kidney, the quality of the transmitted data in adverse drug reaction reports, the timeliness of feedback from clinicians, and the real-time pharmacological and medical analysis by the French network of the regional pharmacovigilance centers made it possible to swiftly identify relevant safety signals. The French National Agency of Medicine was thus able to validate the data and convey their findings very early. This decentralized organization based on medical and pharmacological evaluation of case reports has proven to be efficient and responsive in this unique and challenging healthcare emergency. Springer International Publishing 2020-12-28 2021 /pmc/articles/PMC7769328/ /pubmed/33372244 http://dx.doi.org/10.1007/s40264-020-01034-y Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Current Opinion
Grandvuillemin, Aurélie
Drici, Milou-Daniel
Jonville-Bera, Annie Pierre
Micallef, Joelle
Montastruc, Jean Louis
French Pharmacovigilance Public System and COVID-19 Pandemic
title French Pharmacovigilance Public System and COVID-19 Pandemic
title_full French Pharmacovigilance Public System and COVID-19 Pandemic
title_fullStr French Pharmacovigilance Public System and COVID-19 Pandemic
title_full_unstemmed French Pharmacovigilance Public System and COVID-19 Pandemic
title_short French Pharmacovigilance Public System and COVID-19 Pandemic
title_sort french pharmacovigilance public system and covid-19 pandemic
topic Current Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769328/
https://www.ncbi.nlm.nih.gov/pubmed/33372244
http://dx.doi.org/10.1007/s40264-020-01034-y
work_keys_str_mv AT grandvuilleminaurelie frenchpharmacovigilancepublicsystemandcovid19pandemic
AT dricimiloudaniel frenchpharmacovigilancepublicsystemandcovid19pandemic
AT jonvilleberaanniepierre frenchpharmacovigilancepublicsystemandcovid19pandemic
AT micallefjoelle frenchpharmacovigilancepublicsystemandcovid19pandemic
AT montastrucjeanlouis frenchpharmacovigilancepublicsystemandcovid19pandemic
AT frenchpharmacovigilancepublicsystemandcovid19pandemic